Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia

Jean Yves Reginster, Cyrus C. Cooper, René Rizzoli, John A Kanis, Geoff Appelboom, Ivan Bautmans, Heike A. Bischoff-Ferrari, Maarten Boers, Maria Luisa Brandi, Olivier Bruyère, Antonio Cherubini, Bruno Flamion, Roger A. Fielding, Andrea Ildiko Gasparik, Luc van Loon, Eugene McCloskey, Bruce H. Mitlak, Alberto Pilotto, Suzanne Reiter-Niesert, Yves RollandYannis Tsouderos, Marjolein Visser, Alfonso J Cruz-Jentoft

Research output: Contribution to journalArticle

Abstract

PURPOSE: Sarcopenia is an age-related muscle condition which is frequently a precursor of frailty, mobility disability and premature death. It has a high prevalence in older populations and presents a considerable social and economic burden. Potential treatments are under development but, as yet, no guidelines support regulatory studies for new drugs to manage sarcopenia. The objective of this position paper is therefore to suggest a set of potential endpoints and target population definitions to stimulate debate and progress within the medico-scientific and regulatory communities.

METHODS: A multidisciplinary expert working group was hosted by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, which reviewed and discussed the recent literature from a perspective of clinical experience and guideline development. Relevant parallels were drawn from the development of definition of osteoporosis as a disease and clinical assessment of pharmaceutical treatments for that indication.

RESULTS: A case-finding decision tree is briefly reviewed with a discussion of recent prevalence estimations of different relevant threshold values. The selection criteria for patients in regulatory studies are discussed according to the aims of the investigation (sarcopenia prevention or treatment) and the stage of project development. The possible endpoints of such studies are reviewed and a plea is made for the establishment of a core outcome set to be used in all clinical trials of sarcopenia.

CONCLUSIONS: The current lack of guidelines for the assessment of new therapeutic treatments for sarcopenia could potentially hinder the delivery of effective medicines to patients at risk.

Original languageEnglish
Pages (from-to)47-58
Number of pages12
JournalAging clinical and experimental research
Volume28
Issue number1
DOIs
Publication statusPublished - Feb 2016

Fingerprint

Sarcopenia
Clinical Trials
Pharmaceutical Preparations
Guidelines
Therapeutics
Decision Trees
Premature Mortality
Health Services Needs and Demand
Patient Selection
Osteoporosis
Economics
Muscles
Population

Keywords

  • Aged
  • Clinical Trials as Topic
  • Humans
  • Medication Therapy Management
  • Practice Guidelines as Topic
  • Research Design
  • Sarcopenia
  • Journal Article
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

Cite this

Reginster, J. Y., Cooper, C. C., Rizzoli, R., Kanis, J. A., Appelboom, G., Bautmans, I., ... Cruz-Jentoft, A. J. (2016). Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia. Aging clinical and experimental research, 28(1), 47-58. https://doi.org/10.1007/s40520-015-0517-y

Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia. / Reginster, Jean Yves; Cooper, Cyrus C.; Rizzoli, René; Kanis, John A; Appelboom, Geoff; Bautmans, Ivan; Bischoff-Ferrari, Heike A.; Boers, Maarten; Brandi, Maria Luisa; Bruyère, Olivier; Cherubini, Antonio; Flamion, Bruno; Fielding, Roger A.; Gasparik, Andrea Ildiko; van Loon, Luc; McCloskey, Eugene; Mitlak, Bruce H.; Pilotto, Alberto; Reiter-Niesert, Suzanne; Rolland, Yves; Tsouderos, Yannis; Visser, Marjolein; Cruz-Jentoft, Alfonso J.

In: Aging clinical and experimental research, Vol. 28, No. 1, 02.2016, p. 47-58.

Research output: Contribution to journalArticle

Reginster, JY, Cooper, CC, Rizzoli, R, Kanis, JA, Appelboom, G, Bautmans, I, Bischoff-Ferrari, HA, Boers, M, Brandi, ML, Bruyère, O, Cherubini, A, Flamion, B, Fielding, RA, Gasparik, AI, van Loon, L, McCloskey, E, Mitlak, BH, Pilotto, A, Reiter-Niesert, S, Rolland, Y, Tsouderos, Y, Visser, M & Cruz-Jentoft, AJ 2016, 'Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia', Aging clinical and experimental research, vol. 28, no. 1, pp. 47-58. https://doi.org/10.1007/s40520-015-0517-y
Reginster, Jean Yves ; Cooper, Cyrus C. ; Rizzoli, René ; Kanis, John A ; Appelboom, Geoff ; Bautmans, Ivan ; Bischoff-Ferrari, Heike A. ; Boers, Maarten ; Brandi, Maria Luisa ; Bruyère, Olivier ; Cherubini, Antonio ; Flamion, Bruno ; Fielding, Roger A. ; Gasparik, Andrea Ildiko ; van Loon, Luc ; McCloskey, Eugene ; Mitlak, Bruce H. ; Pilotto, Alberto ; Reiter-Niesert, Suzanne ; Rolland, Yves ; Tsouderos, Yannis ; Visser, Marjolein ; Cruz-Jentoft, Alfonso J. / Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia. In: Aging clinical and experimental research. 2016 ; Vol. 28, No. 1. pp. 47-58.
@article{11f6dfce73e943d3b274c9230815fe2d,
title = "Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia",
abstract = "PURPOSE: Sarcopenia is an age-related muscle condition which is frequently a precursor of frailty, mobility disability and premature death. It has a high prevalence in older populations and presents a considerable social and economic burden. Potential treatments are under development but, as yet, no guidelines support regulatory studies for new drugs to manage sarcopenia. The objective of this position paper is therefore to suggest a set of potential endpoints and target population definitions to stimulate debate and progress within the medico-scientific and regulatory communities.METHODS: A multidisciplinary expert working group was hosted by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, which reviewed and discussed the recent literature from a perspective of clinical experience and guideline development. Relevant parallels were drawn from the development of definition of osteoporosis as a disease and clinical assessment of pharmaceutical treatments for that indication.RESULTS: A case-finding decision tree is briefly reviewed with a discussion of recent prevalence estimations of different relevant threshold values. The selection criteria for patients in regulatory studies are discussed according to the aims of the investigation (sarcopenia prevention or treatment) and the stage of project development. The possible endpoints of such studies are reviewed and a plea is made for the establishment of a core outcome set to be used in all clinical trials of sarcopenia.CONCLUSIONS: The current lack of guidelines for the assessment of new therapeutic treatments for sarcopenia could potentially hinder the delivery of effective medicines to patients at risk.",
keywords = "Aged, Clinical Trials as Topic, Humans, Medication Therapy Management, Practice Guidelines as Topic, Research Design, Sarcopenia, Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Review",
author = "Reginster, {Jean Yves} and Cooper, {Cyrus C.} and Ren{\'e} Rizzoli and Kanis, {John A} and Geoff Appelboom and Ivan Bautmans and Bischoff-Ferrari, {Heike A.} and Maarten Boers and Brandi, {Maria Luisa} and Olivier Bruy{\`e}re and Antonio Cherubini and Bruno Flamion and Fielding, {Roger A.} and Gasparik, {Andrea Ildiko} and {van Loon}, Luc and Eugene McCloskey and Mitlak, {Bruce H.} and Alberto Pilotto and Suzanne Reiter-Niesert and Yves Rolland and Yannis Tsouderos and Marjolein Visser and Cruz-Jentoft, {Alfonso J}",
year = "2016",
month = "2",
doi = "10.1007/s40520-015-0517-y",
language = "English",
volume = "28",
pages = "47--58",
journal = "Aging clinical and experimental research",
issn = "1594-0667",
publisher = "Springer International Publishing AG",
number = "1",

}

TY - JOUR

T1 - Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia

AU - Reginster, Jean Yves

AU - Cooper, Cyrus C.

AU - Rizzoli, René

AU - Kanis, John A

AU - Appelboom, Geoff

AU - Bautmans, Ivan

AU - Bischoff-Ferrari, Heike A.

AU - Boers, Maarten

AU - Brandi, Maria Luisa

AU - Bruyère, Olivier

AU - Cherubini, Antonio

AU - Flamion, Bruno

AU - Fielding, Roger A.

AU - Gasparik, Andrea Ildiko

AU - van Loon, Luc

AU - McCloskey, Eugene

AU - Mitlak, Bruce H.

AU - Pilotto, Alberto

AU - Reiter-Niesert, Suzanne

AU - Rolland, Yves

AU - Tsouderos, Yannis

AU - Visser, Marjolein

AU - Cruz-Jentoft, Alfonso J

PY - 2016/2

Y1 - 2016/2

N2 - PURPOSE: Sarcopenia is an age-related muscle condition which is frequently a precursor of frailty, mobility disability and premature death. It has a high prevalence in older populations and presents a considerable social and economic burden. Potential treatments are under development but, as yet, no guidelines support regulatory studies for new drugs to manage sarcopenia. The objective of this position paper is therefore to suggest a set of potential endpoints and target population definitions to stimulate debate and progress within the medico-scientific and regulatory communities.METHODS: A multidisciplinary expert working group was hosted by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, which reviewed and discussed the recent literature from a perspective of clinical experience and guideline development. Relevant parallels were drawn from the development of definition of osteoporosis as a disease and clinical assessment of pharmaceutical treatments for that indication.RESULTS: A case-finding decision tree is briefly reviewed with a discussion of recent prevalence estimations of different relevant threshold values. The selection criteria for patients in regulatory studies are discussed according to the aims of the investigation (sarcopenia prevention or treatment) and the stage of project development. The possible endpoints of such studies are reviewed and a plea is made for the establishment of a core outcome set to be used in all clinical trials of sarcopenia.CONCLUSIONS: The current lack of guidelines for the assessment of new therapeutic treatments for sarcopenia could potentially hinder the delivery of effective medicines to patients at risk.

AB - PURPOSE: Sarcopenia is an age-related muscle condition which is frequently a precursor of frailty, mobility disability and premature death. It has a high prevalence in older populations and presents a considerable social and economic burden. Potential treatments are under development but, as yet, no guidelines support regulatory studies for new drugs to manage sarcopenia. The objective of this position paper is therefore to suggest a set of potential endpoints and target population definitions to stimulate debate and progress within the medico-scientific and regulatory communities.METHODS: A multidisciplinary expert working group was hosted by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, which reviewed and discussed the recent literature from a perspective of clinical experience and guideline development. Relevant parallels were drawn from the development of definition of osteoporosis as a disease and clinical assessment of pharmaceutical treatments for that indication.RESULTS: A case-finding decision tree is briefly reviewed with a discussion of recent prevalence estimations of different relevant threshold values. The selection criteria for patients in regulatory studies are discussed according to the aims of the investigation (sarcopenia prevention or treatment) and the stage of project development. The possible endpoints of such studies are reviewed and a plea is made for the establishment of a core outcome set to be used in all clinical trials of sarcopenia.CONCLUSIONS: The current lack of guidelines for the assessment of new therapeutic treatments for sarcopenia could potentially hinder the delivery of effective medicines to patients at risk.

KW - Aged

KW - Clinical Trials as Topic

KW - Humans

KW - Medication Therapy Management

KW - Practice Guidelines as Topic

KW - Research Design

KW - Sarcopenia

KW - Journal Article

KW - Research Support, U.S. Gov't, Non-P.H.S.

KW - Review

U2 - 10.1007/s40520-015-0517-y

DO - 10.1007/s40520-015-0517-y

M3 - Article

C2 - 26717937

VL - 28

SP - 47

EP - 58

JO - Aging clinical and experimental research

JF - Aging clinical and experimental research

SN - 1594-0667

IS - 1

ER -